Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/008—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions for determining co-enzymes or co-factors, e.g. NAD, ATP
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
  • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
  • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
  • C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
  • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/58—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving urea or urease
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/902—Oxidoreductases (1.)
  • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Definitions

• the present invention relates to processes and compositions for preparing reagent mixtures for detecting and measuring the presence of certain components in a biological sample, It also relates to the novel reagent mixtures.
• reagents contain one or more biological components such as enzymes, coenzyrnes and/or substrates, etc.
• the reagent has inherently been of a very unstable nature and has very little if any shelf life. To insure the reagent being at optimum strength it must be prepared at or immediately prior to the time the assay is made. In adidtion, heretofore the various components such as the enzymes, coenzyrnes, substrates, etc., included in the reagent have been very unstable. To insure these components being at their optimum it has been necessary for the components to be stabilized in a concentrated form.
• kits containing the several different components which may be dry, or in solutions, has been obtained. If the components are in a dry form, aqueous solutions are formed, and maintained separately until just prior to use.
• the various components for the reagent are present in separate containers and maintained separated from each other. Some of these solutions and particularly those containing the enzymes are necessarily in a concentrated form in order to preserve their activity.
• kits have been capable of producing the desired reactions and permitting the desired assays to be made they have not been entirely satisfactory for numerous reasons. For example, they have not only been very time-consuming and wasteful, but have also required a person of sufficient skill to insure the accurate preparation of the reagents and their being used in the proper manner. Also, because of the possibility of substantial human errors such reagents have induced a certain degree of unpredictable error in the results of the assay.
• the assay materials include components such as enzymes, coenzyrnes and/or substrates which have heretofore been very unstable. Moreover, the combining of such components tends to reduce their stability. However, stabilizers are included that are effective to maintain or preserve the activity of each of the components and of the entire assay material. Each of the components including those containing the enzymes may be stabilized individually and used as such for any desired purpose. Also, the compounds may be combined together to form a new and novel assay material.
• the resultant assay material contains all of the components except Water, for making a liquid reagent that can be used to make a biological assay of the above described type.
• the assay material contains various components such as enzymes, coenzyrnes and/or substrates, etc.
• the material is in a dry, solid form and will be very stable and have a long shelf life. This will permit the assay material to be packaged into containers which are easy to handle and use.
• Each of the containers may include a quantity of the assay material that is just the right amount for making a particular number of assays, for example a single assay.
• the assay material may desirably include an agent which, among other things, is effective to increase the volume of the assay material to a standard size whereby the quantity of the assay material required to produce a single assay will always be a standard amount.
• the contents of one of a standard size container may be mixed with a predetermined quantity of water to produce a liquid reagent 3 that is suitable for making a single assay.
• this agent can facilitate handling during manufacture and increase shelf life.
• a preferred agent is mannitol. It will thus be seen that the possibility of human errors is eliminated and a relatively inexperienced person may prepare the liquid reagent and make the desired assay without any time-consuming measurements, using any large quantities of glassware, etc.
• enzymatic assay is defined as the use of an t enzyme as a component of a reagent for the determination of a substance or another enzyme, or for the determination of an enzyme in a biological sample.
• the present invention is particularly adapted to be embodied in a dry assay material for determining in a specimen of fluid, particularly of biological origin, the quantity or the amount of activity of a certain unknown.
• the unknowns are in a class which for convenience may be divided into four separate groups.
• the groups include enzymes such as carboxylases, dehydrogenases, hydrolases, isomerases, oxidases, phosphorylases and transferases.
• this group includes: lactate dehydrogenase, alkaline phosphatase, glucose, oxidase, muscle phosphorylase, glutamateoxaloacetate transaminase, phosphoenolpyruvate carboxylase, cholinesterase, glutamate-pyruvate transaminase, malate dehydrogenase, acid phosphatase, prostatic acid phosphatase, esterase, diesterase, lipase, amylase, sorbitol dehydrogenase, glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase, alpha-hydroxybutyrate dehydrogenase, aldolase, glutamate decarboxylase, uricase, galactowaldenase, triose phosphate isomerase, carbonic anhydrase, leucine amino-pept'idase, 3-phosphoglyceraldehyde dehydrogenase
• the second group includes biochemical intermediates or metabolites.
• the second group includes: glucose, lactic acid, pynuvic acid, adenosine triphosphate, phenylpyruvic acid, 3 methoxy-4-hydroxymandelic acid, cholesterol, creatinine, creatine, urea, uric acid, aspartic acid and glycine.
• the third group includes chemical constituents of cells or biological fluids which, by way of example, may include dissolved carbon dioxide, triglycerides, protein, starch, glycogen, hemoglobin and insulin.
• the fourth group includes drugs and toxins such as antimycin A, diisopropylfluorophosphate, sulfathiazole, ethanol, acetaldehyde and barbiturates.
• drugs and toxins such as antimycin A, diisopropylfluorophosphate, sulfathiazole, ethanol, acetaldehyde and barbiturates.
• a liquid reagent may be mixed with the specimen to produce an enzymatic reaction.
• the particular reac tion that occurs should produce an effect which can be easily measured.
• the optical density of the assay mixture at some predetenmined Wavelength may change in proportion to the extent of the reaction.
• the liquid reagent is prepared by dissolving a dry, solid assay material in water.
• an assay mixture will be formed that includes a substrate that will enter into the reaction, an enzyme that will catalyze the reaction, and a co-enzyme that will be oxidized or reduced in the course of the reaction so as to produce a desired change in the assay mixture, for example, its optical density. All of the components that are not present in the specimen are contained in the assay material.
• one or more substances are included in the assay material to stabilize the assay material and preserve the activity of the various components.
• one or more buifer substances may also be provided that will be effecttive to maintain the conditions in the assay mixture suitable for the reaction to occur at an optimum rate.
• the assay material is in a dry, powdered form and contains all of the components except water, for producing an enzymatic assay when combined with the specimen.
• the powder may be pre-measured into portions which are of just the right amounts for producing an assay reaction in a single specimen or an integral number of specimens.
• the pre-measured quantity of the assay material may be dissolved directly into a suitable quantity of water to form a liquid reagent.
• the liquid reagent may then be mixed with the specimen to induce the assay reaction in the assay mixture.
• the reagent will not necessarily include an enzyme.
• the assay material is free of any enzymes but includes one or more components such as a substrate that will react at a rate or to the extent that is determined by the amount of activity of the unknnown or enzyme originally present in the specimen.
• a subtrate is included which will react with the unknown and an enzyme included in the reagent, that will catalyze the reaction.
• the first step is to select one or more substrates and one or more enzymes that will be efiective to produce an enzymatic assay reaction and insure its occurring in the desired manner.
• the particular enzymes that are chosen will, of course, depend upon the particular unknown to be assayed and the particular reaction which it is desired to create. However, the enzymes will normally be chosen from a class that includes carboxyl ases, dehydrogenases, hydrolases, isomerases, oxidases, phosphorylases, and transferases.
• this class includes: lactate dehydrogenase, alkaline phosphatase, glucose oxidase, muscle phosphorylase, glutamate oxaloacetate transaminase, phosphoenolpyruvate carboxylase, cholinesterase, glutamate-pyruvate transaminase, malate dehydrogenase, acid phosphatase, prostatic acid phosphatase, esterase, diesterase, lipase, amylase, sorbitol dehydrogenase, glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase, alpha-hydroxybutyrate dehydrogenase, aldolase, glutamate, decarboxylase, uricase, galactowaldenase, triose phosphate isomerase, carbonic anhydrase, leucine aminopeptidase, 3-phosphaoglyceraldehyde dehydrogenas
• enzymes out this type are generally very unstable.
• it has been necessary to keep them in a concentrated form and at low temperatures.
• it has also been usually necessary for the enzyme solution or suspension to include a substantial amount of a salt such as ammonium sulfate to maintain optimal activity.
• one of the steps in the process is to convert the enzyme from a solution to a dry, solid form such as a powder in which the enzyme is very stable.
• one or more stabilizing compounds may be added to the solution containing the enzymes.
• the particular stabilizers added to the enzyme solution will, in part, vary with the particular enzyme that is to be stabilized. However, for enzymes of this type, at least one stabilizer is chosen from one or more. of the following groups. Under some circumstances it has been found to be advantageous to employ a combination of stabilizers which may include a stabilizer from several of the following groups or even a stabilizer from each group.
• the stabilizer may include other polymers containing hydroxy groups or other by .5 drophilic substitute groups which render the resultant polymer essentially soluble in water such as polyvinylpyrrolidine, carbowax and polyvinyl alcohol. This will also insure all of the assay material dissolving rapidly in the water when the reagent is prepared.
• any other polymers which because of large chains or hydrophylic substitutent is only partially soluble in water but which equilibriate with the aqueous phase such as ion exchange resins, ion exchange cellulose, carboxymethyl cellulose.
• a buffer consisting of a hydroxyalkylamine including but not limited to primary amines such as tris (hydroxymethyl) aminomethane or a tertiary amine such as triethanolamine.
• a sequestering or complexing agent such as ethylene diamine tetracetic acid or one of its salts which has been found to be particularly well suited.
• Group IV An inert soluble protein such as bovine serum albumin.
• Group V Salts of a polyvalent anion such as ammonium sulfate, or sodium potassium tartrate, which have been found particularly suitable.
• Sulfhydryl compound such as dithioerythritol, cysteine, or reduced glutathione, which have been found particularly :suitable.
• the enzyme or anzymes in the solution are very stable. It has been found that by adding these stabilizers to the solution, the activity of the enzymes is often increased. This is believed to result from the elimination of the effects of certain inhibitors which are usually present with the enzymes.
• the solution may be diluted by adding water.
• a portion of the liquid may be removed. Preferably, the liquid is removed by evaporation while the solution is maintained at a relatively low temperature. It may thus be seen that a very stable enzyme solution is provided at this point and that the stability of the solution is independent of the concentration of the enzyme or the salts therein and exhibits stability over a wider range of temperature.
• the above described stabilized enzyme solution may be used for numerous purposes as a solution. However, under some circumstances such as the preparation of the present assay material, it may be desirable to convert the solution into a dry mixture or powder containing the enzyme. This may be accomplished by lyophilizing or freeze drying the solution. More particularly, the entire solution is frozen to provide a solid mass and placed under a vacuum. The vacuum is of sufiicient magnitude to cause the frozen liquid to sublimate. The frozen mass is kept under this vacuum for a period sufiicient to insure all of the water, etc., being removed. This will leave a solid residue that contains the enzyme or enzymes in intimate relation with the stabilizers, such as acacia, etc. These stabilizers are effective in preserving the activity of the enzyme for an extended period of time even though the enzyme is in the form of a solid.
• stabilizer broadly relates to a substance which prevents the change or destruction of a reagent component. It has three major aspects in the present invention, namely: (1) to allow for convenient handling of the components during manufacture; (2) to permit the preparation and storage of a component in dry form; and (3) to provide long-term shelf-life of the finished product.
• the residue will normally be in a fluffy or flaky condition. However, if it is desired, the residue may be ground until it is reduced to a finely powdered mixture.
• the grinding may be accomplished by any suitable means such as a ball mill.
• the fact that the powder mixture is substantially dry contributes to the chemical stability of the enzymes. It also contributes to the physical stability of the mixture and substantially eliminates the tendency to compact or become lumpy, etc. Since the mixture can be maintained as a loose powder it will be easy to handle and process. Also, it can be easily measured either volumetrically or gravimetrically.
• a powder is provided that includes one or more enzymes in a very stable form. Since the powder does not include any form of substrate, it can be used as an enzyme for any desired purpose. For example, among other things, the enzyme powder may be employed to complete the preparation of the present assay material.
• the other components such as the buffers, substrates, coenzymes, and bulking-stabilizing agents, may be prepared for mixing with the stabilized enzymes. It is one of the primary purposes of the buffer materials to maintain the conditions suitable for the assay reaction to occur at an optimum rate.
• the buffers will, among other things, be effective to maintain the pH of the liquid reagent.
• the pH of the resultant specimen mixture will still be suitable for the assay reaction to occur.
• the particular buffer material that is employed in any particular assay material will be dependent upon the particular assay reaction to be conducted and the other components in the assay material. However, normally, they will be in a class that includes the salts of polyvalent inorganic anions and organic amines together with the acids and salts thereof.
• the salts of polyvalent inorganic anions may include at least sodium and potassium phosphates and sodium and potassium pyrophosphates.
• organic amines and acids, and their salts may include at least tris (hydroxymethyl) amino-methane and imidazole (and their salts, such as the hydrochloride, succinate, sulfate), succinic, aspartic, and glutamic acids (and their salts such as the sodium, potassium, and lithium), glycylglycine, and glycine.
• the buffer materials may be prepared in the form of a dry powder that is mixed directly with the lyophilized powder containing the enzyme and the stabilizer.
• the resultant powder will contain the enzymes required for the assay reaction. Because of the stabilizers and buffers present in the powder, the enzymes will be very stable. This resultant powder like the enzyme powder first described, will not be hygroscopic, in contrast to corresponding mixtures prepared by lyophilization of the combined buffer and enzyme solutions.
• the substrate is effective for reaction with the unknown in the specimen. Accordingly, the particular substrate that is employed in any particular assay material will be dependent upon the nature of the unknown and the particular assay reaction that it is desired to produce. Normally, the substrate will be in a class of biochemicals whose chemical reactions will be specifically catalyzed by the classes of enzymes previously described.
• alanine alphaor beta-ketoglutaric acid
• aspartic acid aspartic acid
• fructose-1, 6-diphosphate glucose
• the substrate When the assay material is dissolved to form a liquid reagent and the reagent is mixed with the specimen, the substrate will react with the unknown. However, in order for the reaction to occur successfully, it is necessary for the enzyme to catalyze the reaction. The quantity of the substrate and the amount of activity of the enzyme contained in the reagent are in excess of that required to cause all of the unknown to completely react or to react at a desired rate. As a result the only factor that limits the assay reaction will be the quantity or amount of activity of the unknown.
• the substrates When the substrates are in a pure solid dry form, they may be ground into a dry powder suitable for mixing with the lyophilized powder.
• the coenzyme enters into the reaction and is converted from one form to another form.
• the extent to which the coenzyme is converted is determined by the extent to which the assay reaction progresses.
• the coenzyme may be readily converted from one form (such as oxidized) to another form (such as reduced).
• the coenzyme has a light absorption at some particular wavelength only when it is in one of these forms. When it is in the other form, it is transparent at the designated wavelength, although the absorption band may be any desired wavelength that is convenient to use. However, it is desirable that it be distinct from the intense absorption bands of the rest of the components in the assay material and the substances in the specimen.
• the Optical density at the designated Wavelength the amount of the coenzyme converted may be determined. More specifically, by measuring the amount of change or rate of change of the optical density at the designated wavelength, the amount or rate of the assay reaction may be measured. It has been found that the pyridine nucleotides are particularly well suited for this purpose.
• the assay reactions may be observed by always measuring the optical density at this Wavelength.
• Coenzymes of this class have a limited amount of stability in a solid form. They can be stored in a solid form for only short periods of time.
• the stability of the coenzyme may be increased by preparing a lyophilized powder of the coenzyme and acacia. Further increases in the stability of the coenzyme may be obtained by mixing with mannitol. Accordingly, the coenzyme may be ground into a powder and mixed directly with the lyophilized powder containing the enzyme, stabilizer, and buffer.
• This invention teaches that by preparing the various components of the assay material such as the substrates and coenzymes in a dry or solid state, and in a stabilized form before the mixing thereof with the lyophilized stabilized enzyme, a much more stable and easily handled assay material is now provided.
• a bulking-stabilizing agent may be a polyhydric substance such as mannitol, sorbitol, lactose, polyvinyl alcohol or polymers having from 1 to 5 hydroxyl groups per monomeric unit.
• the bulking agent is not active in the assay reaction. Accordingly, the quantity of the bulking agent added to the assay material is not critical and may be varied throughout a wide range. However, the bulking agent performs several unexpected and useful functions. First of all, the :bulking agent tends to further increase the stability of the assay material for several reasons.
• Such agents have the ability to absorb and retain limited quantities of moisture whereby the assay material is not materially affected when exposed to reasonable amounts of moisture. This increases the stability of the assay material and prevents its losing its activity. It has also been found that the bulking agent will also be eflfective in preserving the assay material by increasing the compatibility of its components. It has also been found that bulking agents of this category are also effective in increasing the ability of the assay material to withstand relatively high temperatures, such as 50 C., for longer periods of time. Heretofore, temperatures in this range have caused rapid deterioration of the enzymes, coenzymes, and other components.
• the quantity of the bulking agent added to the assay material may vary over a wide range. Once a batch of the assay material has been prepared, its strength or amount of activity may be determined. The bulking agent may then be added to standardize the assay material to a predetermined level. This will result in the assay material always having a predetermined amount of activity per unit irrespective of the batch in which it is prepared. Of the agents listed above, mannitol is preferred.
• the assay material After the assay material has had the bulking agent added, it may be divided into units of a standard predetermined size. The size normally will be just large enough to make a single assay or an integral number of assays. Each of these units may then be packaged into a container such as a capsule, glass vial, etc.
• a plurality of substantially identical packages such as foil containers or capsules may be provided. Each of these capsules will contain just a sufficient quantity of the assay material for making a single assay of a specimen.
• a package containing the assay material for making the particular assay is selected.
• the assay material contained in the package is all pre-measured and of a predetermined activity. Accordingly, it may be dissolved directly in a standard amount of water so as to form a liquid reagent.
• This liquid reagent is then mixed With the specimen to produce an enzymatic reaction.
• the extent of or the rate at which the reaction occu-rs will be a function of the quantity or amount of activity of the original unknown.
• Every test irrespective of the particular type of assay, will involve the conversion of a coenzyme from one form to another form wherein one form has an optical absorption at a predetermined wavelength. Accordingly, the optical density of the specimen at that wavelength will vary as a function of the unknown. Thus, by measuring the optical density of the medium at different times, it will be possible to compute the quantity or amount of activity of the unknown in the original specimen.
• an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an enzyme in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent While in substantially anhydrous particulate form, comprising a dry coenzyme, a dry buffer, a dry second enzyme capable of catalyzing the conversion of the coenzyme to the other form of the coenzyme, dry substrates, effective to react with the enzyme of which the present quantity or activity is to be determined.
• the invention sought to be patented in a second embodiment of a principal process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an unknown, in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form, and comprising a dry coenzyme, a dry buffer, a dry substrate, effective to react with the unknown of which the present quantity of activity is to be determined, a dry first enzyme capable of catalyzing the reaction of the unknown with the substrate to form an intermediate product, a dry second enzyme capable of catalyzing the reaction of the intermediate product and the coenzyme.
• the invention sought to be patented in a third embodiment of a principal process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an enzyme in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent While in substantially anhydrous particulate form, comprising a dry coenzyme, a dry buffer, and a dry substrate effective to react with the coenzyme, of which the quantity or activity present is to be determined to form the other form of the coenzyme.
• the invention sought to be patented in a fourth embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme malate dehydrogenase, by admixing a stabilizer selected from at least one of tris (hydroxymethyl) aminomethane, its sulfate salt, acacia, ammonium sulfate or ethylenediamine tetraacetic acid.
• the invention sought to be patented in a fifth embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme lactate dehydrogenase, by admixing a stabilizer selected from at least one of tris (hydroxymethyl) aminomethane, its sulfate salt, acacia, ammonium sulfate or ethylenediamine tetraacetic acid.
• the invention sought to be patented in a sixth embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme lactate dehydrogenase, by admixing a stabilizer selected from at least one of polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit.
• the invention sought to be patented in a seventh embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme hexokinase, by admixing a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• the invention sought to be patented in an eighth embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme triose phosphate isomerase, by admixing a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• the invention sought to be patented in a ninth embodiment of a process of making aspect is described as residing in the concept of stabilizing the enzyme glyceraldehyde phosphate dehydrogenase, by admixing a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• a stabilizer selected from at least one of acacia, tris (hydroxymethyl) aminomethane, its sulfate salt, ammonium sulfate or ethylenediamine tetraacetic acid.
• the invention sought to be patented in a tenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glutamate pyruvate transaminase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of the dry substrates alanine and alphaketoglutaric acid, the dry enzyme lactate dehydrogenase, at least one dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylene diamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion, a dry coenzyme consisting of reduced diphosphopyridine nucleotide, a dry buffer from the class that includes the salts of phosphates,
• the invention sought to be patented in an eleventh embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glutamate oxaloacetate transaminase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrates of aspartic acid and alpha ketoglutaric acid, the dry enzyme malate dehydrogenase, at least one dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylenediamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion; a dry coenzyme consisting of reduced diphosphopyridine nucleotide; a buffer from the class that includes the salts of phosphates
• the invention sought to be patented in a twelfth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of aldolase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: a dry substrate comprising fructose-1,6-diphosphate; the dry enzymes triose phosphate isomerase and glyceraldehyde phosphate dehydrogenase; a dry coenzyme consisting of reduced diphosphopyridine nucleotide; 21 dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylene diamine tetracetic acid and its salts, an inert soluble protein and a sulfate anion; a dry buffer from
• the invention sought to be patented in a thirteenth embodiment of a process of making aspect is described as residing in the concept of employing preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence and quantity of glucose in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form, including the combination of: the dry enzymes hexokinase and glucose-6-phosphate dehydrogenase; a dry coenzyme consisting of diphosphopyridine nucleotide; a dry stabilizer from the class that includes mucilageous gums, hydroxyalkylamines, ethylenediamine tetraacetic acid and its salts, an inert soluble protein, and a sulfate anion; a dry buffer from the class that includes mucilaginous gums, hydroxyorganic acids and amines, and the salts of said acids and amines;
• the invention sought to be patented in a fourteenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of adenosine triphosphate in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry enzymes hexokinase and glucose-6-phosphate dehydrogenase; a substrate comprising glucose; a dry coenzyme consisting of triphosphopyridine nucleoxide; a dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylene diamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion; a dry butfer from a class that includes the salts of phosphate anions, organic acids and
• the invention sought to be patented in a fifteenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of malate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate comprising oxaloacetic acid; the dry coenzyme reduced diphosphopyridine nucleotide; a dry stabilizingbulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer from the class that includes the salts of phosphate anions, organic acids and amines, and the salts of said acids and amines; which involves determining the optical density of the solid reagent after forming a liquid reagent therefrom, and again
• the invention sought to be patented in a seventeenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of alpha-hydroxybutyrate dehydrogenase in a biological specimen by mixing therewith a lypholized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate sodium alphaketobutyrate; a coenzyme reduced diphosphopyridine nucleotide; a dry stabilizing-bulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer consisting of the alkali metal phosphates or tris (hydroxymethyl) aminomethane and succinic acid; which involves determining the optical density of the solid reagent after forming a liquid reagent therefrom, and again
• the invention sought to be patented in an eighteenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, interalia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glucose-6-phosphate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent While in substantially anhydrous particulate form including the combination of: the dry substrates sodium salt of glucose 6 phosphate; a coenzyme triphosphopyridinenucleotide; a dry stabilizing-bulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer from the class that includes alkali metal phosphates or tris (hydroxymethyl) aminomethane and succinic acid; which involves determining the optical density of the solid reagent after forming a liquid reagent therefrom, and again following
• the invention sought to be patented in a nineteenth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence and quantity of urea in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: a dry substrate comprising alphaketoglutaric acid; the dry enzymes comprising urease and glutamic dehydrogenase; a dry coenzyme from a class that includes the pyridine nucleotides; preferably a dry activator; a dry stabilizer comprising dithioerythritol Y and sodium potassium tartrate; and a dry butfer that includes at least one of sodium or potassium phosphate, tris (hydroxymethyl) aminomethane, sodium or potassium bicarbonate, sodium or potassium carbonate and glycine; which involves determining the optical density of the solid rea
• the invention sought to be patented in a twentieth embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of creatine phosphokinase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: a dry substrate comprising creatine phosphate; the dry enzymes hexokinase and glucose-6-phosphate dehydrogenase; a dry coenzyme comprising adenosine triphosphate and triphosphopyridine nucleotide; a dry buffer capable of maintaining the pH between 6.5 and 7.5; at least one dry stabilizer selected from mucilaginous gums, hydroxyalkylamines, ethylenediamine tetraacetic acid and its salts, an inert soluble protein and a sulf
• the invention sought to be patented in a twenty-first embodiment of a process of making aspect is described as residing in the concept of preparing an assay reagent, useful, inter alia, as an aid in the clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of lactate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate comprising lithium lactate; a dry coenzyme diphosphopyridine nucleotide; a dry stabilizing-bulking agent comprising polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer from the class that includes the alkali metal phosphates and glycine-rhodium carbonate which involves determining the optical density of the solid reagent after forming a liquid reagent therefrom, and again following a predetermined incubation period after admixing the specimen.
• the invention sought to be patented in a first composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an enzyme in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form and comprising a butter capable of maintaining a predetermined pH of a mixture of the assay reagent and specimen being assayed; substrate(s) effective to react with the enzyme of which the present quantity of activity is to to be determined to form an intermediate product, a coenzyme capable of conversion from one form to another during use, and a second enzyme capable of catalyzing the reaction of the intermediate product(s) with the coenzyme, to form the other form of the coenzyme.
• the invention sought to be patented in a second composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an unknown substance in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form and comprising a buffer capable of maintaining a predetermined pH of a mixture of the assay reagent and specimen being assayed; a substrate effective to react with the unknown substance of which the present quantity or activity is to be determined; an
• the invention sought to be patented in a third composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an enzyme in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form, and including a buffer capable of maintaining a predetermined pH of a mixture of the assay reagent and specimen being assayed, a coenzyme capable of conversion from one form to another during use, a substrate effective to react with the coenzyme catalyzed by the enzyme, of which the present quantity or activity is to be determined to form the other form of the coenzyme.
• the invention sought to be patented in a fourth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glutamate pyruvate transaminase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrates of alanine and alpha-ketoglutaric acid, the dry enzyme lactate dehydrogenase, at least one dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylene diamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion, a dry coenzyme consisting of reduced diphosphopyridine nucleotide, a dry buffer from the class that includes the salts of phosphates, organic acids
• the invention sought to be patented in a fifth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glutamate oxaloacetate transaminase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in a substantially anhydrous particulate form including the combination of: the dry substrates of aspartic acid and alpha ketoglutaric acid; the dry enzyme malate dehydrogenase; at least one dry stabilizer from the class that includes mucilaginous gums, hydr-oxyalkylamines, ethylenediamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion; a dry coenzyme consisting of reduced diphosphopyridine nucleotide; a dry bufier from the class that includes the salts of
• the invention sought to be patented in a sixth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of aldolase, in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: a dry substrate comprising fructose-1,6-diphosphate; the dry enzymes triose phosphate isomerase and glyceraldehyde phosphate dehydrogenase; a dry coenzyme consisting of diphosphopyridine nucleotide; a dry stabilizer from the class that includes mucilaginous gums, hydroxyalkylamines, ethylene diamine tetraacetic acid and its salts, an inert soluble protein and a sulfate anion; a dry buffer from a class that includes the
• the invention sought to be patented in a seventh composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence and quantity of glucose, in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the enzymes hexokinase and glucose-6- phosphate dehydrogenase; the dry coenzymes consisting of triphosphopyridine nucleotide and adenosine triphosphate; a dry stabilizer from the class that includes mucilag inous gums, hydroxyalkylamines, ethylenediamine tetraacetic acid and its salts, an inter soluble protein and a sulfate anion; a dry buffer from a class that includes the salts of phosphate anions, organic acids and amines, and the salts of said acids and amines; and
• composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of adenosine triphosphate, in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combinations of: the dry enzymes hexokinase and glucose-6-phosphate dehydrogenase; a dry substrate comprising glucose; a dry coenzyme consisting of triphosphopyridine nucleotide; a dry stabilizer from the class that includes mucilagenous gums, hydroxyalkylamines, ethylene diamine tetracetic acid and its salts, an inert soluble protein and a sulfate anion; a dry buffer from a class that includes the salts of phosphate anions, organic acids and amines, and the
• the invention sought to be patented in a ninth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of malate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent While in substantially anhydrous particulate form including the combination of: the dry substrate comprising oxaloacetic acid; the dry coenzyme reduced diphosphopyridine nucleotide; a dry stabilizing-bulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buifer from the class that includes the salts of phosphate anions, organic acids and amines, and the salts of said acids and amines.
• the invention sought to be patented in a tenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent, useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of lactate dehydrogenase in a biological specimen by mixing therewith ta lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry sub strate comprising sodium pyruvate; the dry coenzyme reduced diphosphopyridine nucleotide; a dry stabilizingbulking agent from the class that includes polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry bufler from the class that includes the salts of phosphate anions, organic acids and amines, and the salts of said acids and amines.
• the invention sought to be patented in an eleventh composition of matter aspect is described [as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinicial diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of alpha-hydroxybutyrate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent While in substantially anhydrous particulate form including the combination of: the dry substrate sodium alphaketobutyrate; the dry coenzyrne reduced diphosphopyridine nucleotide; a dry stabilizing bulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer consisting of the alkali metal phosphates or tris (hydroxymet-hyl) aminomethane and succinic acid.
• the invention sought to be patented in a twelfth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of glucose-6-phosphate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate sodium salt of glucose-6- phosphate; the dry coenzyme triphosphopyridine nucleotide; a dry stabilizing-bulking agent from the class that includes polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit; and a dry buffer from the class that includes alkali metal phosphates or tris(hydroxymethy1) aminomethane and succinic acid.
• the invention S ught to be patented in a thirteenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, interalia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of urea in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate alphaketoglutaric acid; the dry enzymes urease and glutamic dehydrogenase; a dry coenzyme from: a class that includes the pyridine nucleotides; a dry stabilizer comprising dithioerythritol and sodium potassium tartrate; and a dry buifer that includes at least one of sodium or potassium phosphate, tris-(hydroxymethyl) aminomethane, sodium or potassium bicarbonate, sodium or potassium carbonate and glycine, and preferably, a dry activator.
• the invention sought to be patented in a fourteenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, interalia, as an aid in clinical diagnosis of pat-hological conditions to determine the presence of, quantity of, or amount of activity of creatine phosphokinase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of:
• a dry substrate creatine phosphate the dry enzymes hexokinase and glucoseb-phosphate dehydrogenase; and dry coenzymes adenosine triphosphate and triphosphopyridinenucleotide; a dry buffer capable of maintaining the pH between 6.5 and 7.6; at least one dry stabilizer selected from mucilagenous gums, hydroxyalkylamines, ethylenediamine tetracetic acid and its salts, an inert soluble protein and a sulfate anion; and preferably a dry activator.
• the invention sought to be patened in a fifteenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of lactate dehydrogenase in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: the dry substrate lithium lactate; the dry coenzyme diphosphopyridine nucleotide; a dry stabilizing-bulking agent comprising polyhydric substances with from 1 to hydroxyl groups per monomeric unit; and a dry buffer from the class that includes the alkali metal phosphates and glycine-sodium carbonate.
• the invention sought to be patented in a sixteenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of a substance in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: hexokinaseand at least one dry stabilizer from the class consisting of acacia, ammonium sulfate, tris(hydroxymethyl) aminomethane, and its sulfate salt.
• the invention sought to be patented in a seventeenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of a substance in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particulate form including the combination of: triose phosphate isomerase and a stabilizer that includes one of ammonium sulfate and acacia.
• the invention sought to be patented in a eighteenth composition of matter aspect is described as residing in the concept of a substantially anhydrous solid reagent useful, inter alia, as an aid in clinical diagnosis of pathological conditions to determine the presence of, quantity of, or amount of activity of an unknown in a biological specimen by mixing therewith a lyophilized, stabilized, catalytic reagent while in substantially anhydrous particlate form including the combination of: glyceraldehyde phosphate dehydrogenase and a stabilizer that includes one or more sulfate and acacia.
• the first example of the first embodiment is a solid reagent or assay material that is particularly adapted to be employed for measuring the amount of activity of glutamatepyruvate transaminase (GPT) present in a serum.
• GPT glutamatepyruvate transaminase
• Enzyme lactate dehydrogenase (LDH) Buffer: phosphate buffer (NaH PO +Na HPO Stabilizer: tris-(hydroxymethyl)-aminomethane and its sulfate salt, ammonium sulfate, ethylenediamine tetraacetic acid, acacia and albumin Substrate: alanine and alpha-ketoglutaric acid Coenzyrne: r e d u c e d diphosphopyridine nucleotide (DPNH) Bulking agent: mannitol In order to prepare a large number of units of this assay material or reagent, the following procedure may be employed to produce a batch of a dry assay material or reagent that may then be divided into small quantities and packaged in containers such as capsules. Wherever quantities are specified, they are suitable for preparing a batch that will yield about 10,000 capsules. However, it should be understood that these values may be varied if it is desired to produce larger or smaller batches
• the first step in the procedure is to prepare a tris- EDTA stabilizer solution. This may be accomplished by mixing the chemicals together in approximately the indicated quantities;
• the tris (hydroxymethyl) aminomethane is dissolved in a volume of water that is somewhat less than 1 liter to form a first solution. If it is necessary to assist in this dissolving, the solution may be heated in a water bath. After the tris is completely dissolved, the solution is allowed to cool to about 25 C. and adjusted to about pH 7.5. This adjustment may be accomplished by adding sulfuric acid in the necessary quantities to convert part of the tris (hydroxymethyl) aminomethane to its sulfate salt. After the solution is brought to pH 7.5, sufficient water is added to bring the total volume to 1 liter.
• a second solution is prepared by dissolving the ammonium sulfate in 850 to 900 ml. of water. This solution is adjusted to pH 7.5 by the addition of ammonium hydroxide. The first and second solutions may then be mixed with each other to form a resultant solution. The ethylenediamine tetraacetic acid, tetrasodium salt, may then be added to the resultant solution and dissolved therein to form a bulfer solution which is sometimes hereinafter referred to as the tris-EDTA buffer.
• a dry, lyophilized powder containing the lactate dehydrogenase (LDH) enzyme is then prepared. However, before this powder can be prepared, it is necessary to determine first the amount of activity in the lactate dehydrogenase to be added.
• LDH lactate dehydrogenase
• the activity of the LDH should be standardized at a predetermined level.
• a predetermined level By way of example, in a batch of 10,000 capsules, there may be about 20 10 Wroblewski units [Wroblewski, F., and LaDue, T. 8., Proc. Soc. Exp. Biol. Med. 90, 210 (1955)] for the entire batch, or about 2,000 units per finished capsule.
• the assay may be made by employing the following chemicals in about the indicated amounts:
• the enzyme lactate dehydrogenase is diluted one part to 10,000 by mixing it with the phos phate buffer.
• a small quantity of the diluted enzyme such as 0.1 m1. is mix-ed into a suitable quantity of the buffer solution containing the pyruvate and DPNH.
• the optical density of the mixture at a constant temperature such as 32 C. is then measured at suitable intervals such as one minute for an extended period such as ten minutes.
• the units of enzyme per milliliter of the diluted enzyme can be determined. Then, dividing by the number of milligrams of enzyme per milliliter, it will be possible to find the number of units of enzyme per milligram.
• Lactate dehydrogenase (the exact amount is determined by the above assay) mg 90l00 Acacia m arabic, white powder, U.S.P.) g 2-6 Albumin mg 50-500 Tris-EDTA solution ml 10-30 Ammonium sulfate g l5-40
• These chemicals may be mixed as follows. First, dissolve the acacia in a convenient quantity of distilled water, for example 80 to 160 milliliters. The albumin is then dissolved in a second quantity of water (for example, milliliters). When fully dissolved, the two solutions are mixed. The tris-EDTA prepared in the beginning is then added to the solution.
• the solution is now placed under a vacuum for a period of time that will assure all of the trapped air in the solution being removed. Th amount of the enzyme lactate dehydrogenase determined by the assay is then added to the solution. The resultant solution is then completely mixed to insure a uniform dispersion of the enzyme throughout the entire solution. The solution is then frozen and a vacuum applied to remove all of the water.
• the resultant lyophilized mixture will now be in a dry solid state in a quantity in the general range of about to grams. This dry mixture may then be mixed with the dry crystals of ammonium sulfate. The dry mixture of solids may then be pulverized into a fine powder by any suitable means such as placing it in a ball mill for several hours.
• an assay may be made of the mixture to determine the units of activity of the enzyme lactate dehydrogenase in each milligram of the lyophilized powder.
• the next step is to distribute the lyophilized powder into the capsules. However, if it is desired to delay this step, the lyophilized powder may be stored for extended periods of time in a cold place such as a refrigerator or freezer. If this is done, it is desirable to include a drying agent near the powder to prevent the absorption of any moisture.
• a drying material such as phosphorous pentoxide may be included in the oven to insure a complete drying.
• the alpha-ketoglutaric acid is then added to the mixture formed by the first three compounds.
• the alanine and alpha-ketoglutaric acid form a substrate for the reaction that takes place when assaying the serum for GPT. Accordingly, the exact amounts of these compounds to be used are determined by the optimum amounts needed to produce a satisfactory reaction. Normally, these will be within the range indicated in the above table.
• the resultant mixture of the four compounds is then 20 pulverized into a fine powder, for example, by placing in a ball mill for several hours.
• a small sample may be dissolved in water and the pH determined. If it is necessary, the pH should be adjusted so as to fall within the range of 7.4 to 7.6. If the pH is too low, additional sodium carbonate is added. If the pH is too high, a new mixtur similar to the above is prepared in the same manner. However, this mixture is made definitely deficient in sodium carbonate.
• the second mixture is then blended with the first mixture to bring the pH into the range of 7.4 to 7.6. When the mixture is finished, it is dried again as d scribed above. From this point forward it is important that the powder not be exposed to moisture. Generally, it is best that if the powder is to be exposed to the atmosphere, the relative humidity should be below 15%.
• the pulverized DPNH and the lyophilized powder containing the lactate dehydrogenase may then be added to the powder mixture just prepared above. Before the DPNH is added, it is dried under vacuum in the presence of phosphorous pentoxide to remove moisture. At the time that the lyophilized powder is prepared, the amount of activity of the lactate dehydrogenase is assayed and a quantity of LDH is computed that would produce a total of 20x10 Wroblewski units for the entire batch (if 10,000 capsules are to be prepared), or 2,000 units per capsule or single assay portion. Accordingly, the quantity of the LDH to be blended into the mixture will be determined from that assay.
• the quantity of DPNH to be employed is chosen to produce on optical density that is compatible with spectrometers that are suitable for measuring the optical density during the reaction. Normally, the quantity of DPNH will be such as to produce an optical density of the order of 0.8 at 340 millimicrons. This may 'be checked by dissolving an appropriate quantity of the powder in water (for example, about 4 mg. per 5 ml.) and measuring the optical density.
• a powder that contains the enzyme lactate dehydrogenase, the coenzyme DPNH, and all of the buffers, substrates and stabilizers, to insure the powder being in a stable state that will have a very long shelf life.
• a sample of this powder is withdrawn (being careful not to introduce moisture) and tested. The tests are for the appropriate optical density, homogeneity with respect to the DPNH, and the elfectiveness of the powder to form an assay for glutamate-pyruvate transaminase.
• this powder may be divided into a plurality of small parts that are just large enough to contain the desired 2,000 Wroblewski units and appropriate quantities of buffer, DPNH, L-alanine and alpha-ketoglutarate to perform a GPT determination in 3 ml. Each part may then be enclosed in a suitable package such as a capsule that will protect the mixture from any moisture.
• a desiccant such as an alumina pellet should be placed with the capsule within the package.
• a specimen of the serum is first obtained in a qgantity such as 0.1 milliliter. Following this, the contents of a capsule of this type are dissolved. The resultant solution will form a liquid reagent that is of just the right size to make a single assay and may be mixed directly with the specimen. As soon as the reagent and specimen serum are mixed together, the following reactions will occur:
• the second example of the first embodiment is a solid reagent that is particularly adapted to be employed for measuring the amount of activity of glutamate-oxaloacetic transaminase, or GOT, present in the serum.
• This reagent when fully prepared will consist of a dry mixture containing the following substances:
• Enzyme-malate dehydrogenase Buffer-disodium hydrogen phosphate Stabilizer-acacia, and tris (hydroxymethyl)-amino methane and its sulfate salt, ammonium sulfate and ethylenediamine tetraacetic acid Substrateaspartic acid and alpha-ketoglutaric acid C-oenzymereduced diphosphopyridine nucleotide (DPNH) Bulking agent-mannitol
• MDH Enzyme-malate dehydrogenase
• DPNH alpha-ketoglutaric acid
• the first step in preparing such a batch is normally to prepare a tris-EDTA stabilizer.
• This buffer is a mixture of tris (hydroxymethyl) aminomethane and its sulfate salt, ammonium sulfate, and ethylenediamine tetraacetic acid, tetrasodium salt, and may be prepared in the same manner described in Example A.
• a dry, lyophilized powder containing the malate dehydrogenase or MDH is prepared. This may be accomplished by employing the following chemicals in the indicated ranges:
• the acacia may first be dissolved in a suitable quantity of water such as about 50 milliliters. This solution may then be mixed with the malate dehydrogenase solution and the tris-EDTA solution. After the solution has been thoroughly mixed, it may be placed under a vacuum for a sufiicient interval of time to remove any entrapped air. Following this, the solution may be frozen and placed under a vacuum until all of the moisture is removed therefrom. This will produce a dry lyophilized powder which contains the enzyme malate dehydrogenase together with stabilizers which will be effective to maintain the activity of the malate dehydrogenase at its desired level.
• the lyophilized powder containing the malate dehydrogenase After the lyophilized powder containing the malate dehydrogenase has been prepared, it may be assayed to determine the amount of activity of enzyme malate dehydrogenase present in the powder. This may be accomplished by employing a reagent containing the following chemicals in the indicated quantities:
• Oxaloacetic acid 1 mgjml. 0.1 DPNH, 2 mg./ml. 0.1 Phosphate buffer, 0.1 M, pH 7.5 2.7
• a suitable quantity of the lyophilized powder containing the enzyme malate dehydrogenase may be dissolved in water. This may be accomplished by dissolving about 20 milligrams of powder in about 20 milliliters of water. About 0.02 milliliter of this solution may then be combined with the reagent. When this mixture is made, the DPNH will immediately begin to be converted into DPN. While this reaction is occurring, the solution may be placed in a suitable spectrophotometer and the optical density in the reagent measured at suitable increments of time, for example, every minute.
• an average may be provided which will indicate the amount of activity of the malate dehydrogenase in the lyophilized powder.
• a change in the optical density of 0.001 per minute indicates an activity of 1 unit. From this, it will be possible to calculate the amount of the lyophilized powder containing the malate dehydrogenase that is required to produce an activity in the ranges of about 8 to 20 10 units.
• the dry lyophilized powder containing the malate dehydrogenase may be prepared for packaging in a capsule. This may be accomplished by employing the following chemicals in the indicated ranges:
• the alpha-aspartic acid, alpha-ketoglutaric acid, disodium hydrogen phosphate and sodium carbonate may all be mixed together and ground into a fine powder by any suitable means such as placing in a ball mill for about 6 to 10 hours. Following the mixing, a sample such as about milligrams of the mixture may be dissolved in a suitable quantity of water such as 5 milliliters. The pH of this solution should be between 7.4 and 7.6.
• a suitable quantity of sodium carbonate may be added to raise the pH to the desired level. If the pH is too high, additional quantities of alpha-aspartic acid and alpha-ketoglutaric acid may be added.
• the ball milling may be repeated-the powders are mixed with mannitol by ball milling or the like, and then dried at 40 C. under vacuum in the presence of phosphorous pentoxide.
• the DPNH and the calculated quantity of lyophilized powder containing malate dehydrogenase may be added to the mixture.
• the amount of DPNH added is such that one ten-thousandth of the resulting mixture When dissolved in 3 milliliters of water will have, for convenience of measurement, an optical density at 340 millimicrons of 0.8 to 1.0. This mixture may then be ground in a ball mill.
• a powder that contains the enzyme malate dehydrogenase, together with the stabilizers acacia, tris-EDTA, ammonium sulfate and ethylenediamine tetra-acetic acid so as to insure the powder being very stable and having a very long shelf life wherein the enzyme activity will not deteriorate.
• the powder includes a bufIer-disodium hydrogen phosphate and substrates alpha-aspartic acid and alpha-ketoglutaric acid that will insure the desired reaction occurring when an assay is made. A sample of this powder is withdrawn (being careful not to introduce moisture) and tested.
• this powder may be divided into a plurality of small parts that are just large enough to form a liquid reagent suitable for making one assay of a specimen.
• the entire bulk of the powder may then be divided into units or parts which contain the desired amount of activity.
• Each of these parts may then be packaged in a suitable container such as a capsule. If a pharmaceutical gelatin capsule is used, a desiccant such as an alumina pellet should be placed with the capsule within the package. It is desirable that the same size capsule be employed at all times irrespective of which batch the capsule is produced from. Accordingly, the capsule may be of a sufiiciently large size to insure packaging of all variations.
• a bulking agent such as mannitol may then be added to each of the parts so as to bring its volume up to an amount that will just fill the capsule.
• a specimen of a serum or other biological fluid is first obtained in a suitable quantity.
• a capsule of this example is dissolved in a suitable quantity of Water.
• the resultant solution will form a liquid reagent that is of just the right size and strength to make a single assay of the serum. Accordingly, this liquid reagent may then be mixed with the specimen. As soon as the reagent and specimen are mixed together, the following reactions will occur:
• the third example of the first embodiment is a solid reagent that is particularly adapted to be employed for measuring or assaying the amount of activity of aldolase present in a serum.
• This reagent when fully prepared will consist of a dry mixture of the following substances:
• iEnzyme triosephosphate isomerase and glyceraldehydephosphate dehydrogenase Buffer: glycine and sodium pyrophosphate Stabilizer: acacia, albumin, ethylene diamine tetra-acetic acid Substrate: fructose-1,6-diphosphate Coenzyme: DPN
• Decouplcr sodium arsenate
• Bulking agent mannitol
• the first step is to prepare a standard liquid assay system which may be used at several different points in the procedure.
• the assay liquid includes the following:
• the resultant mixture is allowed to incubate for some interval of time such as 5 minutes.
• the optical density of the solution is then measured at 340 millimicrons by means of a suitable spectrophotometer. Thereafter, the optical density is repeatedly measured at this wavelength periodically for some predetermined interval of time such as 3 minutes.
• a reference indicating the effectiveness or amount of activity in the standard assay liquid will be provided. Future assays in the present process may then be compared with this reference to determine whether they are within acceptable ranges.
• an assay powder may be prepared by mixing the following chemicals in about the indicated ranges:
• the buffer powder may then be placed under a vacuum in the presence of a moisture absorbing agent for a suflicient period of time to insure any moisture being removed. Following the drying, the buffer powder may be further pulverized by placing in a ball mill for an extended period of time. A small sample of the buffer may be 25 dissolved in water and the pH of the solution measured. The pH of this solution should be about 8. If it is not sufficiently close to this, the required quantities of either salt may be added to the buffer to adjust the pH to the required level and the grinding repeated.
• the next step is to grind the sodium arsenate into a fine powder and add it to the glycine-sodium pyrophosphate buffer.
• the resultant combination is then ball milled to form a fine powder and dried under a vacuum for an extended period of time.
• this powder has been prepared, it is desirable to test the powder to make sure that there are no inhibitors which may impair the operation of the assays. This determination may be made by preparing a solution similar to the standard liquid assay. However, the just prepared powder is substituted for the first pair of chemicals in the list for the standard assay.
• the same dilution of the aldolase is then mixed with the new essay liquid and the resultant changes in the optical density at 340 millimicrons measured as described in connection *with the standard. If the optical density varies, the same as the reference, the preparation of the lyophilized enzymes triose phosphate isomerase and glyceraldehyde phosphate dehydrogenase may proceed.
• the next step will then be to dissolve the acacia into about one liter of distilled water.
• the ethylene diamine tetra-acetic acid and the albumin are then added to the solution and the solution thoroughly mixed. It should he noted that during the mixing a certain amount of foaming may occur. Steps should be taken to keep the foaming to a minimum. After the solution is completed, it should be placed under a vacuum for a sufiicient period of time to remove any air that may still be trapped in the solution.
• the enzymes triose phosphate isomerase and glyceraldehyde phosphate dehydrogenase are added to the solution.
• the solution should be very thoroughly mixed to insure a uniform dispersion of the enzymes throughout all portions of the solution. Since these enzymes in this solution tend to be somewhat unstable and lose their activity, the solution should be frozen as soon as they are properly suspended in the liquid.
• the frozen solution is then placed under a vacuum and all of the water removed therefrom.
• a sample should be assayed to determine if they still have adequate activity.
• This assay is made by comparing the activity of the powder with the activity of the standard liquid assay described in the beginning of this example.
• a new assay solution is prepared by substituting a solution prepared from the lyophilized powder for the enzyme solutions.
• the optical density should vary in the same manner as the reference. It is desirable that this powder be stored under refrigeration and kept as dry as possible until the process is to be continued.
• the buffer arsenate mixture and the lyophilized powder containing the enzymes may be mixed together.
• the fructose-1,6-diphosphate and the DPN are added to the mixture and the entire mixture pulverized to a very fine powder by any suitable means such as ball milling.
• the resultant powder will constitute, in bulk, a dry powdered reagent containing the enzymes triosephosphate isomerase and glyceraldehydephosphate dehydrogenase and the coenzyme DPN together with stabilizers that will maintain the activity of the enzymes for extended periods of time.
• this solid reagent In order to make this solid reagent into a form that is more readily usable, it may be divided into units that are of a size suitable for assaying a single specimen. These units may then be enclosed in a suitable package for preventing the absorption of any moisture. Since there may be some variations in the volumes of the units between successive batches, it may be desired to add a bulking agent such as mannitol to each batch that will bring the volume of each unit up to some predetermined volume. The mannitol likewise aids in conferring additional stability to the reagent. The bulked powder may then be packaged in suitable containers such as capsules.
• a bulking agent such as mannitol
• a suitable sample of the serum or biological fluid is first obtained. Following this, the contents of one of the capsules is dissolved into a standard amount of water such as 3 to 5 milliliters. This will produce an active liquid reagent that is of just the right size to make a single assay of one specimen of the foregoing size. Furthermore, the activity of this reagent will be of a predetermined level. The liquid reagent may then be mixed directly with the specimen in a suitable test tube. As soon as the reagent and specimen or serum are mixed together, the following reactions will occur:
• aldolase fructose-1,6-diphosphate Shydroxyacetone phosphate-l-3-glyceraldehydeph0sphate triosephosphate isomerase 3-hydroxaeetonepl1osphate 3-glyceraldehydephosphate glyceraldehydephosphate 3-glycoraldehydephosphate-l-DIN dehydrogenase 3-ph0sphoglycerate
• the fructose-1,6-diphosphate Since the fructose-1,6-diphosphate is supplied by the capsule, it will be present in an abundant quantity. As a result, the rate at which it is converted directly into 3- glyceraldehyde phosphate will be limited only by the amount of activity of the aldolase. In addition, since the triosephosphate isomerase is supplied in abundant quantities, the rate at which the 3-hydroxyacetonephosphate is produced and converted into the 3-glyceraldehyde phosphate will be limited only by the amount of activity of the aldolase.
• the rate at which the 3-glyceraldehydephosphate is produced is directly related to the amount of activity of the aldolase originally present in the specimen, the rate at which the DPN is converted to DPNH will also be determined by the aldolase.
• the rate at which the DPNH is being produced may be determined by measuring the rate of change of the optical density of the specimen at 340 millimicrons. Knowing this rate of change, by employing well-known equations, the amount of aldolase originally present in the specimen may be computed.
• EXAMPLE D The fourth example of the first embodiment in this group is a solid reagent that is particularly adapted to be employed for measuring the quantity of glucose present in a serum.
• This reagent when fully prepared will have the following components that include the indicated chemicals:
• Enzyme hexokinase and glucose 6 phosphate dehydrogenase Buffer: tris(hydroxy) methylaminomethane succinate Stabilizer: acacia, tris(hydroxy)methylaminomethane sulfate and ammonium sulfate Substrate: none Accelerator: insulin and magnesium sulfate Coenzymes: adenoaine triphosphate and triphosphopyridine nucleotide Bulking agent: mannitol In order to prepare a large number of capsules or individual assay portions of this reagent, the following procedure may be employed to produce a batch of dry reagent that may then be divided into small quantities and packaged into capsules. Wherever quantities are specified in this example, they are suitable for preparing a batch that will yield about 10,000 capsules. It should be understood, however, that these values are for illustrative purposes only and may be varied to satisfy any particular requirement.
• the first step in this procedure is to prepare a suitable buffer solution.
• This buffer solution may be prepared by mixing the following chemicals together in about the indicated quantities:
• a dry lyophilized powder containing the enzymes hexokinase and glucose-6-phosphate dehydrogenase may then be prepared by mixing the following chemicals in the indicated ranges:
• ammonium sulfate 1 M, pH 7.5 ml 75-150 (Adjusted with ammonia) ml 75150 Insulin mg 50-750 Hexokinase mg 100 Gl-ucose-6-phosphate dehydrogenase mg 100
• the tris-buifer is first prepared by making a solution containing tris (hydroxymethyl) aminomethane and adding a sufficient quantity of sulfuric acid to make a 0.2 molar solution with a pH of 7.4 to 7.6. The acacia, ammonium sulfate and insulin are then mixed with the tris-sulfate solution to form a homogenous solution.
• the resultant solution is then placed under a vacuum for a sufficient period of time to remove all of the air entrapped therein.
• the hexokinase and glucose-6-phosphate dehydrogenase are then mixed into the solution to obtain a homogeneous mixture.
• the solution is then frozen and placed under a vacuum until .all of the water is removed. This will result in a dry or lyophilized homogeneous powder containing the enzymes.
• the lyophilized powder may be assayed to determine the amount of activity of the hexokinase and glucose-6-phosphate dehydrogenase enzymes by employing the following procedure and using the indicated quantities of the following chemicals:
• Tris-succinate buffer solution (1.7 g./100 ml.) ml 1
• Triphosphopyridine nucleotide
• the tris-succinate buffer solution is first formed by dissolving 1.7 grams of the buffer prepared in the first step of this example in 100 milliliters of water. The rest of the listed solutions .are mixed with the buffer and the water to form a homogeneous mixture. The optical density of this solution is then measured at 340' millimicrons. A predetermined quantity of a glucose solution of known concentration is then added to the foregoing solution. This will Cal cause a reaction wherein the TPN will be converted to TPNH. Since the TPN will be present in an abundant supply, the only factor which will limit the reaction is the quantity of glucose. After the reaction has been completed, the optical density of the solution is again measured at 340 millimicrons.
• the above assays are preferably made by employing several different standard solutions of glucose, for example, 200, 400 and 600 mg. percent of glucose.
• the difference between the optical densities before and after the reaction should be equal to 0.230 times the mg. percent of the standard glucose solution divided by 100. In the event the difference is not equal to or very close this predicted value, the enzymes do not have an adequate amount of activity. However, of the changes of optical density are equal to or very close to the predicted value, the enzymes are sufliciently active and the mixture may be prepared for packaging into the capsules. This may be accomplished by employing the following chemicals in the indicated ranges:
• Tris-succinate buffer (prepared above) 100-250 Magnesium sulfate, n-hydrate 1 120 TPN 12-18 ATP 10-18 Lyophilized enzyme mixture 80-200 1 An equivalent amount of magnesium may be added as the glutamate or aspartate salt.
• This assay powder forms the assay powder and contains the enzymes hexokinase and glucose-6-phosphate and dehydrogenase together with the stabilizers acacia, tris sulfate buffer and ammonium sulfate to insure the enzymes maintaining their activity for extended periods of time.
• this assay powder also contains the coenzymes ATP and TPN together with the buffer tris succinate to insure the desired assay reactions occurring when an assay is being made.
• this powder may now be divided into units which .are of just the right size for performing a single assay of a single specimen.
• an assay may be made to determine the amount of activity of the enzymes in the mixture. This assay may be accomplished in substantially the same manner as described above in connection with the assaying of the lyophilized powder containing the enzymes.
• liquid reagents may be dissolved in suitable quantities of water to form liquid reagents.
• glucose i.e., 200, 400 and 600 mg. percent of glucose
• the resultant changes in optical density may be measured. From the results of these tests, the amount of activity of the enzymes contained in the powder can be determined.
• the resultant reaction is allowed to continue until all of the glucose has been converted.
• the amount of time that is required for this conversion to be completed is determined by the amount of activity of the enzymes. Therefore, in order to determine the amount of activity to be included in each capsule, it is first necessary to determine the amount of time to be allowed for the reaction to be completed. To do this, a convenient test period or interval is arbitrarily selected, for example, 5 minutes. Some fractional part of this interval, for example, 3 minutes, is then selected during which the reaction is virtually completed. This will guarantee the reaction being completed at the end of the test period. The quantity of assay powder required for each capsule is then determined. With this quantity of activity in each capsule, it may be safely assumed that the reaction has been complete prior to the end of the test interval.
• the capsule size may be made larger than the largest units that may be encountered.
• a bulking agent such as mannitol may then be added to the assay powder so that the resultant units will just fill the capsule.
• a specimen of the serum is first obtained in a suitable quantity for making an assay.
• the optical density of this specimen is first measured at 340 millimicrons.
• the contents of one of the capsules may be dissolved in a suitable quantity of water to thereby form a liquid reagent that is of the right size and activity for making one assay.
• This liquid reagent may then be combined with the serum so that the following reactions will occur:
• the glucose that was originally present in the serum will be converted into glucose-6-P. This, in turn, will react with the TPN to produce the TPNH. Since the capsule supplies an excess of its chemicals, the only factor that limits the reaction is the quantity of the glucose originally present. Therefore, the amount of TPNH finally produced will be a function of the original quantity of glucose.
• the foregoing reaction are allowed to continue for the duration of the test period or until they have been completed and the glucose is exhaused.
• the optical density of the specimen is measured again at 340 millimicrons. Since the TPNH will absorb the light at this wavelength, the difference in the optical density before and after the reactions will be a result of the change in the amount of the TPNH produced. Since the change in the quantity of TPNH will be a direct function of the quantity of glucose originally present in the specimen, the change in optical density may be. employed to calculate the glucose originally present.
• EXAMPLE E The last example of the first embodiment in this group is a solid reagent that is particularly adapted to be employed for measuring the amount of activity of adenosine triphosphate or ATP present in a biological sample.
• This reagent fully prepared will consist of a dry mixture of the following solid substances:
• Enzyme ' hexokinase and drogenase Buffer: tris (hydroxymethyl) aminomethane succinate Stabilizer: acacia, tris (hydroxymethyl) aminomethane and ammonium sulfate Substrate: glucose Accelerator: insulin and magnesium sulfate Coenzyme: TPN
• The'first step in this procedure is to prepare a suitable buffer solution.
• the buffer employed is substantially identical to the tris buffer used in Example D and consists of a mixture of tris (hydroxymethyl) aminomethane and succinic acid. These chemicals may be mixed in substaritially the same manner as described in 'Example D to produce a dried buffer powder that when dissolved in glucose-6-phosphate dehy- 30 water wil produce a solution having a pH between 7.4 and 7.6.
• a dry lyophilized powder containing the enzymes hexokinase and glucose-6-phosphate dehydrogenase may then be prepared by combining the following chemicals in the indicated ranges:
• the tris-sulfate solution is prepared first by dissolving tris (hydroxymethyl) aminomethane and adding a sufficient quantity of sulfuric acid to make a 0.2 molar solution with a pH 7.4 to 7.6.
• the acacia, ammonium sulfate and insulin are completely mixed with the tris-sulfate to form a homogenous solution.
• any air entrapped therein may be removed by placing the solution under a vacuum.
• the enzymes hexokinase and glucose-6-phosphate dehydrogenase are mixed into this solution. This solution should be thoroughly mixed to insure the enzymes being completely dispersed therein. While uniformly mixed, the solution is competely frozen. While in the frozen state, it is placed under a vacuum until all of the moisture is removed. This will leave a homogeneous dry powder containing the enzymes.
• This lyophilized powder may then be assayed to determine the amount of activity of the enzyme present by employing the following chemicals in the indicated amounts to form a reagent:
• the tris-succinate buffer solution is prepared by dissolving 3.4 grams of the buffer prepared in the beginning of this example in 100 milliliters of Water. Following this, the indicated quantities of the rest of the solutions are combined and mixed with the indicated quantity of water. After the reagent has been completed, its optical density at 340 millimicrons is measured. Following this, a standard adenosine triphosphate solution containing 2 uM/rnl. may be added to the mixture. When this occurs, the reaction subsequently described will occur. However, the solution is allowed to stand for an adequate period of time to insure that the reaction has been completed. After the completion of the reaction, the optical density at 340 millimicrons is again measured. By comparing the optical densities, the amount of change produced as a result of the reaction can be determined.
• Tris-succinate buffer (prepared above) 100-250 Magnesium sulfate, heptahydrate -120 T PN 12-18 Glucose, anhydrous 25-100 Lyophilized enzyme mixture 80-200 usually 24 hours.
• the powder is ready fordividing into suitable units and packaged into capsules.
• the activity of the powder must first be determined. This is accomplished by dissolving a small sample of the specimen in a suitable quantity of water such as 2.9 ml. The assay test described above may then be repeated. By measuring the change of optical density produced by the assay reaction, the amount of activity of the enzymes in the powder maybe determined.
• this powder When this powder is dissolved in water, it will make a reagent that will cause a reaction involving the adenosine triphosphate (ATP) present. This reaction will continue until all of the ATP has disappeared. The amount of time required for this to occur will be determined by the amount of activity of the enzymes present. Accordingly, in order to compute the amount of the assay powder to be placed in each capsule, an interval convenient for making the test must first be chosen. For example, this may be minutes. The size of the units into which the assay powder is divided will then be such that the reaction will be virtually completed in some fraction of the test period, for example 3 minutes.
• an interval convenient for making the test may be chosen. For example, this may be minutes. The size of the units into which the assay powder is divided will then be such that the reaction will be virtually completed in some fraction of the test period, for example 3 minutes.
• a standard capsule size is selected that will always accommodate the largest unit of powder. After the size of the units is determined, a suitable quantity of a bulking and stabilizing agent such as mannitol or its equivalent may be added to bring the volume to just the right size to fill the standard-sized capsule.
• a bulking and stabilizing agent such as mannitol or its equivalent
• a large number of identical capsules will be produced that are suitable for assaying the amount of adenosine triphosphate (ATP) present in a serum.
• the stabilizers tris-sulfate, acacia and ammonium sulfate will be effective to stabilize the enzymes and preserve their activity for extended period of time.
• the tris-succinate buffer and the glucose substrate and TPN coenzyme will insure the assay reaction occurring.
• a suitable sample of the serum is first obtained.
• the optical density of the sample diluted with water to the same volume as the assay is first determined at a wavelength of 340 millimicrons.
• the contents of one of the capsules is then dissolved in a standard quantity of water such as 3 milliliters. This will create a liquid reagent of the correct size and activity for making an assay of one serum sample.
• This liquid reagent may then be combined with the sample of serum whereby the following reactions will occur:
• the reactions are allowed to continue for the duration of the test interval. However, long before the expiration of this interval, the reactions will have been completed. After the reactions have been completed or at the end of the test interval, the optical density of the sample is measured again at 340 millimicrons. Since the TPNH will absorb light at this wavelength, the difference between the otpical densities before and after the reactions will be a result of the changes in the amount of the TPNH produced. Since the change in the quantity of TPNH is a function of the quantity of ATP originally present in the specimen, this quantity of ATP can be computetd from the change in the optical density.
• an assay material is provided that is very similar to the assay material in the previously-described embodiment.
• the assay material is also a dry solid suit I able for prepackaging into containers such as capsules or foil wrappers containing just the right quantity for making a single assay or predetermined number of assays.
• the assay material contains all of the components, except water, for making an assay. The contents of one package is dissolved in water to form a liquid reagent effective to create an enzymatic reaction of the same type created by the preceding embodiment.
• the assay materials in this embodiment are particularly adapted for measuring the amount of activity of an enzyme originally present in the specimen. Accordingly, in this embodiment, the assay material does not necessarily include an enzyme. However, it does include at least one substrate for producing the desired assay reaction and a coenzyme that will enter into the reaction and be converted from one form to another form.
• the coenzyme may be of the same class as in the preceding embodiment. Accordingly, the reactions produced by these assay materials may also be observed by measuring the optical density of the specimenassay mixtureat the same wavelength.
• a buffer mixture may be prepared first.
• the exact composition of the butfer will vary with the particular assay reaction to be produced.
• the buffers are very similar to those in the first embodiment and will be in a class that includes the salts of polyvalent inorganic anions and the organic amines together with the acids and salts thereof.
• the salts of polyvalent inorganic anions may include at least sodium and potassium phosphates, sodium and potassium pyrophosphates.
• the organic amines and their acids and salts may include at least tris (hydroxymethyl) amino methane and imidazole and their salts such as the hydrochloride, succinate, sulfate, succinic, aspartic and glutamic acids and their salts such as the sodium, potassium and lithium, glycylglycine and glycine. Normally, when these buffers have been fully prepared, they will be a dry powder mixture.
• buffer it is one of the purposes of the buffer to maintain the conditions such as the pH in the reagent and specimen-- assay mixturesuitable for the desired assay reaction to occur.
• the substrates employed in this embodiment will, of course, depend upon the particular assay reaction. However, they will normally be in a class of compounds whose chemical reactions will be specifically catalyzed by the classes of enzymes previously referred to and whose activity is being measured. These substrates may also be reduced to a dry powdered form suitable for mixing with the buifer materials.
• the coenzymes will also depend upon the particular assay reaction. However, the coenzyme is preferably from the same class as in the preceding embodiment. This will insure all of the assay reactions being effective to produce changes in the optical density of the specimens at a standard wavelength.
• the coenzymes may be from the class that includes the pyridine nucleotides when in the oxidized form these coenzymes will also have an absorption in the region of about 340 millimicrons.
• the coenzyme may be in a solid form suitable for being powdered. Accordingly, the powdered buflfers, substrates and coenzymes may all be mixed together to form the assay material.
• the assay material will always be prepared as a dry solid material.
• the material may be finely powdered for prepackaging and for dissolving in a liquid such as water to form a liquid reagent.
• the various assay materials of this embodiment may also have their volume increased to some predetermined standard level. This will insure all of the resultant units being of identical sizes.
• bulking agents of this type are effective, increase the stability of the assay mixture of this embodiment. Among other things, because of its moisture absorbing abilities, it protects the assay material against deterioration resulting from exposure to moisture. Also, the bulking agents are effective to assist in stabilizing substrates such as oxaloacetic acid.
• This acid is an unstable compound particularly when it is in a buffer solution having a pH of about 7.5.
• the acid can be made very stable and in a form that is compatible with the other components in the desired reaction.
• the oxaloacetic acid will be in a form that may be easily handled and used. As will become apparent, the oxaloacetic acid when in this prepared form will be particularly suitable for use in preparing an assay material for use in making assays for malate dehydrogenase.
• this embodiment may also provide a plurality of substantially identical packages such as metal foil packets, capsules, etc.
• Each of these packages will contain just a sufiicient quantity of the assay material for making a single assay of a specimen or distinct and accurate multiples of a single assay.
• the contents of one package is dissolved in a standard amount of water so as to form a liquid reagent.
• This liquid reagent is then mixed with the specimen to produce an assay reaction. The extent of or the rate at which this reaction occurs will be a function of the amount of activity of the enzyme present in the specimen.
• the rate at which this reaction occurs can be measured by measuring the optical density of the specimen different times to determine the rate of change of the optical density. From this, it will be possible to compute the amount of activity of the enzyme originally present.
• the first example of the second embodiment is a solid assay material that is particularly adapted to be employed in preparing a reagent for assaying the amount of malate dehydrogenase or MDH present in a serum.
• this assay material When this assay material is fully prepared, it will consist of the dry mixture of the following substances:
• Buffer sodium phosphate and potassium phosphate
• Substrate oxaloacetic acid
• Coenzyme DPNH Stabilizer: mannitol
• the following procedure may be employed to produce a batch of dry assay material that may be divided into small quantities and packaged into standard size capsules. Wherever quantities are specified, they are suitable for preparing a batch that will yield about 10,000 capsules. It should be understood, however, that the amounts indicated may be varied to satisfy any particular requirements.
• the assay material may be prepared by first combining the following materials in the indicated amounts to form a dry mixture:
• These three ingredients are first ground into a fine powder by any suitable means such as in a ball mill. After these materials have been finely ground and are thoroughly mixed, a small quantity of the powder may be dissolved in a suitable quantity of water.
• the pH of the resultant solution should be in the range of about 7 .4 to 7.6. If it is not within this range, additional quantities of one of the first two ingredients may be added to the mixture to bring the pH into the desired range.
• mannitol is used in the present instance, it may be replaced with sorbitol or lactose or one of the polymers thereof having from 1 to 5 hydroxyl groups per monomeric unit.
• the powder may then be dried under a vacuum of 0.2 mm. Hg at 25 for about 48 to 72 hours. It is also desirable for the individual powders to be dried in this manner before they are mixed together.
• the coenzyme DPNH may be prepared as a fine powder and added to the foregoing mixture.
• the coenzyme may be powdered and added at the same time as the other powders.
• the quantity of the oxaloacetic acid to be added to the mixture should be carefully determined by the following assay.
• a reagent is prepared by combining the indicated amounts of the following solutions:
• the phosphate may be prepared by dissolving the phosphate to form a 0.10 molar solution.
• the DPNH solution is formed by dissolving approximately 4 milligrams of the DPNH in 1 milliliter of water.
• the reagent is then prepared with a sufficient quantity of the malate dehydrogenase in 0.1 ml. to cause a change of the optical density at 340 millimicrons on the order of 0.02 per minute under the conditions of the assay.
• the quantity of the oxaloacetic acid added to the foregoing powder is then adjusted to produce the same rate of change in the optical density.
• the amount of oxaloacetic acid that is required to be added to the assay mixture to produce the optimum rate of change in the optical density can thus be determined.
• This quantity of the oxaloacetic acid and the DPNH are then added to the assay mixture.
• the amount of DPNH that is added will be determined by the optical density which is desired in the specimen and reagent mixture. Normally, this will be in the general range of about 0.8 CD. at 340 m
• a dry powder is provided that contains the substrate oxaloacetic acid and reduced diphosphopyridine nucleotide together with mannitol (as an example). As long as this powder is maintained dry, it is very stable and will have a very long shelf life.
• This liquid reagent may thus be mixed with the specimen. As soon as the reagent and the specimen are mixed together, the following reaction will occur:
• MDH oxaloacetic acid DPNH malic acid DPN Since the oxaloacetic acid and the DPNH are supplied from the assay material, they will be in excess of the minimum amount required to complete the foregoing assay reaction. However, this reaction is dependent upon being catalyzed by the enzyme malate dehydrogenase present in the serum. Accordingly, the only factor which will limit the rate at which the DPNH which is converted into DPN will be the amount of activity of the malate dehydrogenase originally present in the specimen.
• the optical density of the specimen-assay mixture is then measured at 340 millimicrons at periodic intervals. This will permit the rate of change of the optical density to be compiled which, in turn, will permit the amount of activity of the malate dehydrogenase to be computed.
• the second example of the second embodiment is a solid assay material that is particularly adapted to be employed in preparing a reagent for assaying the amount of lactate dehydrogenase or LDH presents in a serum.
• this assay material When this assay material is fully prepared, it will consist of the dry mixture of the following substances:
• Buffer disodium hydrogen phosphate and potassium dihydrogen phosphate
• Substrate sodium pyruvate
• Coenzyme DPNH Stabilizer: Mannitol G.
• These three ingredients are first ground into a fine powder by any suitable means such as in a ball mill. After these materials have been finely ground and are thoroughly mixed, a small quantity of the powder may be dissolved in a suitable quantity of water.
• the pH of the resultant solution should be in the range of about 7.4 to 7.6. If it is not within this range, additional quantities of one of the first two ingredinents may be added to the mixture to bring the pH into the desired range.
• the buffer powder may then be dried under vacuum and in the presence of a moisture absorbing agent such as phosphorus pentaoxide (P at a temperature of about 50 C. until all of the moisture is removed.
• P phosphorus pentaoxide
• a coenzyme and substrate powder may be prepared by combining the following materials in the indicated ranges:
• the exact amount of the sodium pyruvate is critical. Accordingly, the quantity of the sodium pyru- V3126 to be added to the mixture should be carefully determined by means of a series of assays.
• a plurality of assay liquids may be prepared by combining the indicated amounts of the following solutions:
• Phosphate buffer 1.0 g. phosphate powder above/ 10 ml. ml 2.8 DPNH 4 mg./ml. mg 0.1 Serum ml 0.020
• the phosphate butter may be prepared by dissolving 1 gram of the phosphate containing the powder described above in 10 milliliters of water.
• the DPNH solution is formed by dissolving approximately 4 milligrams of the DPNH in 1 milliliter of water.
• a serum containing a suitable quantity of lactate dehydrogenase may be used as a source of enzyme.
• about 32 milligrams of the sodium pyruvate to be employed is dissolved into about 10 milliliters of water.
• the indicated quantities of the serum, DPNH and buffer solutions may be combined with each other to form an assay liquid.
• a suitable quantity of the pyruvate solution for example, 0.05 milliliter is then added to the assay liquid.
• the optical density of the solution at 340 millimicrons is measured as periodic intervals and recorded. Following this, the foregoing procedure is repeated with increasing amounts of the pyruvate solution (for example, 0.10 milliliter, 0.15 milliliter, 0.20 milliliter, etc.).
• the optical density of the assay liquids at 340 millimicrons is periodically measured and recorded. This procedure is continued until the exact amount of the pyruvate solution required to produce the maximum rate of change of the optical density at 340 millimicrons is determined.
• the amount of sodium pyruvate that is required to be added to the assay mixture to produce the optimum rate of change in the optical density can then be determined. This quality of the pyruvate and the DPNH are then added to the assay mixture.
• the amount of DPNH that is added will be determined by the optical density which is desired in the specimen-reagent mixture. Normally, this will be in the general range of about 0.8 CD. at 340 m
• the resultant mixture may be ground and pulverized by any suitable means such as ball mill to form the powdered assay material. Following this, the assay material may be dried under vacuum.
• a dry powder that contains the substrate sodium pyruvate and reduced diphosphopyridine nucleotide together with mannitol (as an example).
• this powder may now be divided into a plurality of small parts that are just large enough to be mixed with water to form a liquid reagent suitable for making a single assay of a serum.
• Each of these parts may then be packaged into a suitable container such as a capsule for subsequent use. If it is desirable that the same size capsule be employed at all times, the standard size may be large enough to accept the largest quantity of the powder that will ever be needed.
• the quantity of the bulking and stabilizing agent, mannitol, added to the assay material may be selected to bring the total volume of each part up to a size that will just fill the capsule.
• a specimen of the serum is first octained.
• the assay material in one of the capsules of this example is dissolved in a suitable quantity of water. This will form a liquid reagent having the right size for making a single assay of the serum.
• This liquid 37 reagent may thus be mixed with the specimen. As soon as the reagent and the specimen are m'nred together, the following reaction will occur:
• EXAMPLE H This exemplifies a solid assay material that is particularly adapted to be employed in preparing a reagent for assaying the amount of alpha-hydroxybutyrate dehydrogenase or HBDH present in a serum.
• this assay material When this assay material is fully prepared, it will consist of the dry mixture of the following substances:
• buffer disodium hydrogen phosphate and potassium dihydrogen phosphate
• Substrate sodium alpha-ketobutyrate
• Coenzyme DPNH Stabilizer: mannitol Grams Disodium hydrogen phosphate 200-400 Potassium dihydrogen phosphate 40-80 Mannitol LOGO-2,000
• the first two ingredients are first ground into a fine powder by any suitable means such as in a ball mill. After these materials have been finely ground and are thoroughly mixed, a small quantity of the powder may be dissolved in a suitable quantity of water.
• the pH of the resultant solution should be in the range of about 7.4 to 7.6. If it is not within this range, additional quantities of one of the first two ingredients may be added to the mixture to bring the pH into the desired range.
• the buffer powder may then be dried under vacuum and in the presence of a moisture absorbing agent such as phosphorus pentoxide (P at a temperature of about C. for two days.
• the buffer consists of a mixture of disodium hydrogen phosphate and potassium dihydrogen phosphate; however, equivalent buffers such as those composed of alkali rnetal phosphate or tris(hydroxymethyl) aminomethane and succinic acid may be employed.
• the buffer used should be an anhydrous powder before dissolving in water at which time the resultant solution should have a pH in the range of 7.4 to 7.6.
• a coenzyme and substrate powder may be prepared by combining the following materials in the indicated ranges:
• the exact amount of the sodium alpha- 38 ketobutyrate is critical. Accordingly, the quantity of the sodium alpha-ketobutyrate to be added to the mixture should be carefully determined by means of a series of assays.
• a plurality of assay liquids may be prepared by combining the indicated amounts of the following solutions:
• Phosphate buffer 1.0 g. bulfer-mannitol above/ 1 0 ml 2.8 DPNH 4 mg./ml 0.1
• the phosphate buffer may be prepared by dissolving 1 gram of the phosphate containing the powder described above in 10 milliliters of water.
• the DPNH solution is formed by dissolving approximately 4 milligrams of the DPNH in 1 milliliter of water.
• a serum containing a suitable quantity of lactate dehydrogenase may be used as a source of enzyme.
• about 320 milligrams of the sodium alphaketobutyrate to be employed is dissolved into about 10 milliliters of water.
• the indicated quantities of the serum, DPNH and buffer solutions may be combined with each other to form an assay liquid.
• a suitable quantity of the alpha-ketobutyrate solution for example, 0.05 milliliter is then added to the assay liquid.
• the optical density of the solution at 340 millimicrons is measured at periodic intervals and recorded. Following this, the foregoing procedure is repeated with increasing amounts of the keto butyrate solution (for example, 0.10 milliliter 0.15 milliliters, 0.20 milliliter, etc.).
• the optical density of the assay liquids at 340 millimicrons is periodically measured and recorded. This procedure is continued until the exact amount of the ketobutyrate solution required to produce the maximum rate of change of the optical density at 340 millimicrons is determined.
• the amount of sodium alpha-ketobutyrate that is required to be added to the assay mixture to produce the optimum rate of change in the optical density can then be determined.
• This quantity of the sodium alpha-ketobutyrate and the DPNH are then dried under vacuum at room temperature for 12 to 24 hours and added to the buifer-mannitol mixture.
• the amount of DPNH that is added will be determined by the optical density which is desired in the specimen. Normally, this will be in the general range of about 0.8.
• the resultant mixture may be ground and pulverized by any suitable means (which prevents exposure to excess moisture) such as a ball mill form the thoroughly mixed powdered assay material. Following this, the assay material may be dried under vacuum.
• a dry powder that contains the substrate sodium alpha-ketobutyrate and coenzyme diphosphopyridine nucleotide (reduced) together with mannitol (as an example).
• this powder may now be divided into a plurality of small parts that are just large enough to be mixed with water to form a liquid reagent suitable for making a single assay of a serum.
• Each of these parts may then be packaged into a suitable container such as a capsule for subsequent use. It it is desirable that the same size capsule be employed at all times, the standard size may be large enough to accept the largest quantity of the powder that will ever be needed.
• the quantity of the buliking and stabilizing agent, mannitol, added to 0118 essay material may be selected to bring the total volume of each part up to a size that will just fill the capsule.
• Mannitol has been found to be the preferably bulkingstabilizing agent; however, any equivalent material which dissolves readily, does not interfere with the chemical reaction of the assay, is not hygroscopic and contains negligible moisture, may be an equivalent contemplated by the inventor for carrying out his invention.
• Equivalent materials are typically polyhydric substances and polymers of said polyhydric substances with from 1 to 5 hydroxyl groups per monomeric unit.
• a specimen of the serum is first obtained.
• the assay material in one of the capsules of this example is dissolved in a suitable quantity of water. This will form a liquid reagent having the right size for making a single assay of the serum.
• This liquid reagent may thus be mixed with the specimen. As soon as the reagent and the specimen are mixed together, the following reaction will occur:
• the fourth example of the second embodiment is a solid assay material that is particularly adapted for making a liquid reagent that may be employed for assaying the amount of activity of glucose-6-phosphate dehydrogenase.
• This material when fully prepared will consist of a dry mixture of the following:
• Buffer tris-succinate Substrate: glucose-fi-phosphate, sodium salt Coenzyme: TPN
• Accelerator magnesium sulfate, glutamate or aspartate Stabilizer: mannitol
• the following procedure may be employed to produce a batch of a dry reagent or assay powder that may be divided into small quantities and packaged into capsules. Wherever quantities are specified in this example, they are suitable for preparing a batch that will yield about 10,000 capsules. It should be noted that the values are for illustrative purposes only and may be varied to satisfy any particular requirement.
• the first step in making an assay material of this form is to prepare a buffer.
• a buffer In the present example,
• the mixture of the buffer includes the following materials
• the tris (hydroxymethyl) aminomethane and the succinic acid are first mixed together and ground into a fine powder in the same manner as described before. This Will provide a tris-succinate buffer that is in the form of a fine powder, which when dissolved in water will form a solution having a pH of 7.4 to 7.6.
• the magnesium sulfate may be added thereto (an equivalent amount of magnesium as its glutamate or aspartate salt may be used). This will be in solid form and accordingly may be mixed directly with the buffer and the resultant mixture ground into a fine powder.
• the first solution is formed by dissolving 10 milligrams of glucose-6-phosphate sodium salt in 10 milliliters of water (10, molar test).
• the second solution is also formed by dissolving 11.5
• a third solution is prepared by dissolving 430 milligrams of the mixture of the magnesium sulfate and trissuccinate buffer in 1.8 milliliters of water.
• a fourth solution is also prepared that includes tris (hydroxymethyl) aminomethane, succinic acid and magnesium sulfate which are obtained from sources differing from those used in preparing the magnesium-buffer mixture, but are dissolved to form a solution that is the equivalent of the third solution.
• a first test solution is formed by combining 0.1 milliliter of the first or glucose- 6-phosphate solution, 0.1 milliliter of the second or triphosphopyridine solution, 1.8 milliliters of the third or buffer mixture and enough water to make the final volume equal to 2.9 millilters.
• a second test solution is formed by combining the buifer solution obtained from the original or step 1, 0.1 milliliter of the glucose-6-phosphate solution, 0.1 milliliter of the second or triphosphopyridine nucleotide solution, 1.8 milliliters of the fourth or equivalent of the prepared buffer and sufficient water to make a total of 2.9 milliliters.
• 0.1 milliliter of a solution of glucose-6-phosphate dehydrogenase is placed in one of the test solutions.
• the changes in the optical density of the solution occurring at 340 millimicrons are measured.
• the same amount of glucose-6-phosphate dehydrogenase (0.1 milliliter) is then added to the second test solution.
• the changes in the optical density of this solution are then measured. If the changes for the two solutions are of the same, the magnesium-buffer mixture contains no inhibitors and the assay material may be prepared.
• the assay material may be prepared -by mixing the following materials together in the indicated amounts:
• a dry powder that contains the substrate and coenzyme that are to react with each other to form the assay reaction.
• This powder is very stable and will have a long shelf life. Accordingly, it may be divided into a plurality of small parts that are just large enough to be mixed with water to form a liquid reagent suitable for making a single assay of a serum. Each of these parts may then be packaged into a suitable container such as a capsule for subsequent use. If it is desirable that the same size capsule be employed at all times, the standard size may be large enough to accept the largest quantity of the powder that will ever be needed.
• a bulking and stabilizing agent such as mannitol is added so as to increase the total volume and improve the stability.
• a specimen of the serum is first obtained.
• the assay material in one of the capsules of this example is dissolved in a suitable quantity of water. This will form a liquid reagent having the right size for making a single assay of the serum.
• This liquid reagent may thus be mixed with the specimen. As soon as the reagent and the specimen are mixed together, the following reaction will occur:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (20)

Applications Claiming Priority (1)

Publications (1)

Family

ID=24243318

Family Applications (1)

Country Status (7)

Cited By (50)

Families Citing this family (8)

Citations (3)

Family Cites Families (1)

• 1966
  • 1966-06-30 US US561757A patent/US3413198A/en not_active Expired - Lifetime
• 1967
  • 1967-06-01 IL IL28098A patent/IL28098A/en unknown
  • 1967-06-20 NL NL6708570A patent/NL6708570A/xx unknown
  • 1967-06-28 CH CH913967A patent/CH514841A/de not_active IP Right Cessation
  • 1967-06-28 GB GB29939/67A patent/GB1192046A/en not_active Expired
  • 1967-06-28 GB GB29934/67A patent/GB1191697A/en not_active Expired
  • 1967-06-28 GB GB29940/67A patent/GB1163409A/en not_active Expired
  • 1967-06-30 DE DE1598325A patent/DE1598325B1/de active Granted
  • 1967-06-30 BE BE700778D patent/BE700778A/xx not_active IP Right Cessation
  • 1967-06-30 DE DE19671598321 patent/DE1598321A1/de active Pending
  • 1967-06-30 DE DE19671598326 patent/DE1598326A1/de active Pending

Patent Citations (3)

Also Published As

Similar Documents